Other Events ·
CEO David Stamler to present at Canaccord Genuity Drug and Device Conference on October 12
ATHEAlterity Therapeutics Ltd
Alterity Therapeutics announced that CEO David Stamler will deliver a corporate presentation and host investor roundtables at the Canaccord Genuity Drug and Device Conference on Monday, October 12, 2026. The company is a clinical-stage biotechnology firm focused on developing disease-modifying therapies for neurodegenerative diseases, specifically Multiple System Atrophy (MSA). Its lead asset, ATH434, has shown efficacy in Phase 2 trials, and the company is preparing to initiate a pivotal Phase 3 trial.